Upcoming Challenges With Sequencing Frontline Treatment of CLL

November 16, 2018
Susan M. O'Brien, MD

Susan M. O’Brien, MD, discusses the challenges with the 3 oral agents approved in chronic lymphocytic leukemia.

Susan M. O’Brien, MD, associate director for clinical sciences, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, discusses the challenges with the 3 oral agents approved in chronic lymphocytic leukemia (CLL).

Ibrutinib (Imbruvica) is the only agent approved in the frontline setting currently, but venetoclax (Venclexta) is now being investigated in a randomized clinical trial with obinutuzumab (Gazyva), another novel anti-CD20 monoclonal antibody, O’Brien says. Based on that data, there may be more options for the frontline treatment of CLL, but it would make sequencing more complicated.